Companies: 10,795·Total market cap: $144.5T
Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc.

DCPHNASDAQHealthcare
$25.59
+$0.02(+0.08%)
Market Cap$2.2B
P/E Ratio
52W High$25.61
52W Low$9.9
Overview

Deciphera Pharmaceuticals, Inc. (DCPH) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · DCPH · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-2.21dcph eps ttm · dcph earnings per shareEarnings history
PE Ratio (TTM)dcph pe ratio ttm · dcph price to earningsPE Ratio deep dive
Revenue (TTM)$174.9Mdcph revenue ttm · dcph annual revenueFull revenue history
Dividend YieldNo Dividenddoes dcph pay dividends · dcph dividend yieldDividend history
Shares Outstanding85.1Mdcph shares outstanding · dcph floatShares outstanding history
Next EarningsTBAdcph earnings date · dcph next earningsEarnings history

Financial Snapshot

Full Financials
FY 2023Revenue$163.4M▲ +21.87% YoY
202120222023
deciphera pharmaceuticals, inc. revenue · dcph revenue 2023
FY 2023Net Income-$194.9M▼ 8.95% YoY
202120222023
deciphera pharmaceuticals, inc. net income · dcph profit 2023
FY 2023EPS$-2.29▲ +3.38% YoY
202120222023
dcph eps · deciphera pharmaceuticals, inc. earnings per share 2023
TTM:Revenue: $174.9MNet Income: -$190.4MEPS: $-2.21View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy26 analystsis dcph a buy · dcph analyst rating
Strong Buy
0
Buy
13
Hold
12
Sell
1
Strong Sell
0
12-Month Price Target
$25.00Low
$25.59Current
$26.32Avg Target2.85% upside
$30.00High
dcph price target · dcph 12 month forecast

Total: 26 · Buy rate: 50.0%

The DCPH analyst consensus is Buy, based on ratings from 26 Wall Street analysts over the past 3 months. The average 12-month price target is $26.32, representing +2.85% upside from the current price of $25.59.

Stock Performance

Full History
1D+0.00%
1W+0.00%
1M+0.00%
3M+63.93%
YTD+54.62%
1Y+86.92%
5Y+17.60%

About Deciphera Pharmaceuticals, Inc.

CEOSteven L. Hoerter
IPO DateSep 28, 2017
Employees355
CountryUS

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing innovative therapies to significantly improve outcomes for cancer patients. Their core strategy involves tackling the …

what is deciphera pharmaceuticals, inc. · dcph stock overview · deciphera pharmaceuticals, inc. company profile · who is deciphera pharmaceuticals, inc. ceo · dcph NASDAQ · deciphera pharmaceuticals, inc. headquarters · deciphera pharmaceuticals, inc. business segments

About Stock Overview & Key Data

Deciphera Pharmaceuticals, Inc. (DCPH) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ since Sep 28, 2017. As of the latest trading session, DCPH stock price is $25.59, with a market capitalization of $2.2B. The stock has returned +86.92% over the past 12 months and +54.62% year-to-date.

According to 26 Wall Street analysts, the consensus rating for Deciphera Pharmaceuticals, Inc. stock is Buy, with an average 12-month price target of $26.32. In fiscal year 2023, Deciphera Pharmaceuticals, Inc. reported revenue of $163.4M and net income of -$194.9M. For detailed data — including Deciphera Pharmaceuticals, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Deciphera Pharmaceuticals, Inc. (DCPH) stock price is $25.59. The stock is traded on NASDAQ under the ticker symbol DCPH. The 52-week range is $9.90 – $25.61.

DCPH stock priceDCPH quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice